Skip to content
OpenCapital
Get started

Utah Medical Products UTMD Cash & Equivalents

Cash & Equivalents at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$1.02B+49.0%
TFX
TeleflexTFX
$329.55M+16.8%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
$139M+19.6%
IAR
Integra LifeSciencesIART
$236.81M-1.0%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$488.08M+23.4%
PDE
Pro-Dex, Inc.PDEX
$9.99M+123%

Other financials

Income statement

See full
Revenue$8.7M-10.2%
Gross profit$5.3M-4.6%
Operating income$2.6M-18.6%
Net income$2.6M-14.4%
EPS (diluted)$0.82-10.9%

Balance sheet

See full
Total debt$210.0K—
Total equity$120.4M+2.8%
Total assets$124.4M+1.5%

Cash flow

See full
Operating cash flow$3.1M-30.4%
CapEx$130.0K-29.3%
Free cash flow$3.0M-30.4%

Valuation

See full
Market cap$219.63M+26.4%
Enterprise value$132.44M+42.5%
P/E20.3×+6.4×
P/S5.9×+1.4×

Profitability

See full
Gross margin57.9%-0.4pp
Operating margin28.8%-3.9pp
Net margin28.9%-4.1pp
FCF margin34.7%0.0pp

Returns & leverage

See full
Return on equity9.1%-1.4pp
Debt / equity0×—
Current ratio28.6×+6.3×

Where this comes from

Reported directly by Utah Medical Products in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Utah Medical Products’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Utah Medical Products's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Utah Medical Products's cash & equivalents?
Utah Medical Products (UTMD) reported cash & equivalents of $87.41M in Q1 2026.
How has Utah Medical Products's cash & equivalents changed year-over-year?
Utah Medical Products's cash & equivalents increased by 4.9% year-over-year, from $83.33M to $87.41M.
What is the long-term trend for Utah Medical Products's cash & equivalents?
Over 5 years (2020 to 2025), Utah Medical Products's cash & equivalents has grown at a 10.7% compound annual growth rate (CAGR), from $51.59M to $85.76M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.